HEALTHY U MEDICAID

PRIOR AUTHORIZATION REQUEST FORM **PULMOZYME®**

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U Prior Authorization Department at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

·	ou have prior authorization questions, please call for assistance: 38			and and Chake making approximation	
DISC	claimer: Prior Authorization request forms are subject to change in accord	Jance w	itii reae	erai and State notice requirements.	
Dat	e: Member Name:		ID#:		
DO	B: Gender:	Gender:		Physician:	
Off	ice Phone: Office Fax:	Office Fax:		Office Contact:	
Hei	ght/Weight:				
<i>rea</i> Pro	ferred products has not been successful, you must submit which preferre son for failure. Reasons for failure must meet the Health Plan medical naduct being request: Pulmozyme® (dornase alfa) Sing/Frequency:				
	If the request is for reauthorization, proceed to	o reaut	horizat	tion section	
	Questions	Yes	No	Comments/Notes	
1.	Does the member have a confirmed laboratory diagnosis of cystic fibrosis?				
2.	Is the prescriber a pulmonologist or a physician with expertise in caring for cystic fibrosis patients?				
3.	Has the member had a trial and failure to hypertonic saline?			Please provide documentation	
4.	If requesting twice daily dose of Pulmozyme®, has the member trialed once daily dosing?			Please provide documentation	
	REAUTHORIZATION				
1.	Is the request for reauthorization of therapy?				
2.	Has the member's therapy been re-evaluated within the past 6 months?				
3.	Has the therapy shown to be effective with an improvement or stabilization in condition?			Please provide documentation	
4.	Does the member show a continued medical need for the therapy?			Please provide documentation	
	nat medications and/or treatment modalities have been tried in the me of treatment, reason for failure, treatment dates, etc.	ne past	for this	s condition? Please document	

Additional information:
Physician's Signature:

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

Policy PHARM- HU-045 Origination Date: 01/01/2022 Reviewed/Revised Date: 07/31/2023 Next Review Date: 07/31/2024 Current Effective Date: 10/01/2023

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.